TEM-PCR™ (Target Enriched Multiplex Polymerase Chain Reaction) is a novel multiplex PCR amplification strategy invented by Dr. Jian Han in 2003. Dr. Han had been in China combating the epidemic SARS outbreak at the time and became frustrated with the limitations of traditional PCR. This led him to investigate ways of multiplexing PCR to detect multiple targets. On a flight back to the U.S. from China, Dr. Han conceived of the basic process for achieving true multiplex PCR by implementing nested primers at lower concentrations with the addition of a universal primer set for the large-scale amplification. This process was proven later that year and Dr. Han named it TEM-PCR™.
Diatherix Eurofins founder Dennis Grimaud became involved with TEM-PCR™ soon after its inception. Dr. Han recruited Grimaud to become the CEO of his company, Genaco Biomedical Products, after the invention of TEM-PCR™. From 2005-2008 Genaco participated in multiple studies such as this correlation study demonstrating TEM-PCR™ to be “… both accurate and robust enough to be used in a routine clinical setting.” Also during that time, TEM-PCR™ was named both the Frost and Sullivan award for Technology Innovation and Leadership of the Year and runner up for the Wall Street Journal Medical Technology Innovation of the Year Award. Since 2008, Diatherix Eurofins has been using TEM-PCR™ to develop and perform multiplex PCR panel testing for infectious disease diagnostics. Diatherix Eurofins was the first CLIA certified laboratory to be awarded an Emergency Use Authorization (EUA) from the FDA for H1N1-09 during the 2009 pandemic. Diatherix Eurofins holds all associated rights and patents for TEM-PCR™.